No Data
NurExone's ExoPTEN, Loaded With SiRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
NurExone Announces Further Expansion of ExoPTEN Patent Coverage
Updates From NurExone: Growth Conference Presentation and Website Relaunch
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
NurExone Announces Expansion of ExoPTEN Patent Coverage With Notice of Allowance for Japanese Patent Application
NurExone Announces Voting Results From 2024 Annual Meeting of Shareholders
No Data